Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Solymbic

- PMLiVE

Amgen and Boehringer drugs win FDA breakthrough status

Leukaemia drug and Pradaxa antidote will benefit from accelerated regulatory processes

Novartis building

Novartis pulls EMA application for expanded Tasigna use

And Boehringer confirms it won't seek approval for faldaprevir as it exits hepatitis C

- PMLiVE

Biosimilar Lantus leads CHMP opinions

Boehringer and Lilly’s insulin one of six new medicines recommended for EU approval

- PMLiVE

AbbVie takes PARP inhibitor into third phase III trial

Veliparib under investigation for use in advanced breast cancer

- PMLiVE

Avastin first biologic backed in EU for resistant ovarian cancer

Roche drug recommended in latest round of CHMP opinions

Shire Basingstoke

Shire spells out why AbbVie takeover is a bad idea

Talks up its growth prospects as an independent company

Kite Pharma once again looks to Amgen

William Go and Jeff Aycock fourth and fifth senior figures to join from Amgen this year

Shire Basingstoke

Shire turns down takeover offer from AbbVie

Marks third time UK pharma company has turned down AbbVie's advances

- PMLiVE

UCB taps EU for €75m in R&D funding

Agrees innovative risk-sharing finance deal with European Investment Bank

- PMLiVE

ADA: Lilly/Boehringer insulin glargine matches Lantus

Biosimilar demonstrates equal efficacy to Sanofi’s big-selling diabetes treatment

AbbVie closes in on US approval of all-oral hepatitis C regimen

FDA grants priority review to company’s protease inhibitor ABT-450 regimen

- PMLiVE

Creating a brand identity for biosimilars

How to ensure a replicated biologic is seen as more than just a tribute brand

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links